RxDoctor Payments Data

Arlin French, DO

Ophthalmology · Clarkston, MINPI 1538154125

Payments from drug & device makers

$3,735in general payments, 2019–2025

Across 103 payments — averaging $36.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Johnson & Johnson Surgical Vision, Inc.$226
  • Carl Zeiss Meditec USA, Inc.$189
  • NEW World Medical,inc.$182
  • Rxsight Inc$181
  • Ocular Therapeutix, Inc.$156
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,69999%
  • Education$351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,735 in reported general payments places this provider in the 75th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$232,861
Medicare patients
840
Services billed
2,061

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine57$68,709
LumiganBimatoprost63$29,641
Timolol Maleate199$11,654
Prednisolone Acetate322$11,000
Bromfenac Sodium40$10,505
Cyclosporine17$8,808
Latanoprost419$8,540
ProlensaBromfenac Sodium24$8,341
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol29$5,266
Brimonidine Tartrate56$3,062
Ofloxacin185$2,089
Travoprost11$1,815
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha54$754
ValacyclovirValacyclovir Hcl11$697
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat35$687

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$126$98,350120 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$89$8,34124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Clarkston

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →